Neurocrine (NBIX) $2.5B Deal for Soleno Therapeutics
Published on Β· Source: ft.com
AI Summary
Summarized by AI from the source belowNeurocrine Biosciences (NBIX) is nearing a deal exceeding $2.5 billion to acquire Soleno Therapeutics. Soleno Therapeutics has developed the first commercialized drug aimed at treating extreme hunger associated with Prader-Willi syndrome. This acquisition could enhance Neurocrine's product portfolio and expand its market capabilities in the biotech sector. The transaction highlights ongoing consolidation within the pharmaceutical industry, particularly focused on innovative treatments for rare diseases.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
